Day One Biopharmaceuticals, Inc. Stock Price, News & Analysis

Day One Biopharmaceuticals (NASDAQ: DAWN), a company focused on developing targeted therapies for life-threatening diseases, has scheduled its Q2 2025 financial results conference call and webcast for Tuesday, August 5, 2025, at 4:30 p.m. ET.

The event will include a discussion of financial results and corporate updates. Investors can access the live webcast through Day One's Events page, and a replay will be available for 30 days following the presentation.

Day One Biopharmaceuticals (NASDAQ: DAWN) has appointed Michael Vasconcelles, M.D., as Head of Research & Development. Dr. Vasconcelles brings over 25 years of experience in oncology research, development, and health technology. He previously served as Executive VP at ImmunoGen, where he led the company's transformation into a global biotech enterprise. His extensive career includes leadership roles at Flatiron Health, Unum Therapeutics, Takeda, and Genzyme. In his new role, Dr. Vasconcelles will oversee Day One's research, development, and medical affairs infrastructure, focusing on driving OJEMDA's growth and building a pipeline of first- or best-in-class medicines for patients of all ages with life-threatening diseases.

Day One Biopharmaceuticals (NASDAQ: DAWN) reported strong Q1 2025 financial results, highlighting continued growth of their flagship product OJEMDA (tovorafenib). Net product revenue reached $30.5 million in Q1, with prescriptions increasing 16% compared to Q4 2024. The company has achieved $87.7 million in total OJEMDA revenue since launch, representing over 2,500 prescriptions. Key developments include Ipsen's regulatory filing acceptance by the European Medicines Agency and progress in clinical trials. The company ended Q1 with a strong cash position of $473.0 million. Despite growth in revenue, Day One reported a net loss of $36.0 million for Q1 2025, improved from a $62.4 million loss in Q1 2024. R&D expenses were $39.6 million, while SG&A expenses increased to $29.3 million to support OJEMDA's launch.

Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its first quarter 2025 financial results and corporate updates. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.

Day One Biopharmaceuticals (DAWN) reported its Q4 and full year 2024 financial results, highlighting strong performance of its flagship drug OJEMDA. The company achieved $29.0 million in Q4 OJEMDA net product revenues, a 44% increase from Q3, and $57.2 million for the full year 2024.

Since OJEMDA's launch in April 2024, over 1,600 prescriptions have been written. The drug received Exclusively Pediatric designation from CMS, reducing its Medicaid and 340B minimum rebate percentage to 17.1%. The company reported a net loss of $65.7 million for Q4 and $95.5 million for full year 2024.

R&D expenses increased to $227.7 million for 2024, primarily due to DAY301-related payments. The company maintains a strong financial position with $531.7 million in cash and equivalents as of December 31, 2024.

Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, February 25, 2025, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2024 financial results and corporate progress. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.

Day One Biopharmaceuticals (Nasdaq: DAWN) reported preliminary unaudited 2024 net product revenue of approximately $57.2 million for OJEMDA™ (tovorafenib). The fourth-quarter revenue for OJEMDA reached around $29.0 million. The company ended 2024 with approximately $531.7 million in cash, cash equivalents, and short-term investments, a significant increase from $366.3 million at the end of 2023.

OJEMDA received FDA accelerated approval in April 2024, making it the first FDA-approved therapy for relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion, rearrangement, or BRAF V600 mutation. Additionally, CMS approved OJEMDA exclusively for pediatric indications, reducing its Medicaid and 340B minimum rebate percentage from 23.1% to 17.1%.

Day One advanced its pipeline by progressing the Phase 3 FIREFLY-2 clinical trial and initiating the Phase 1a/b trial for DAY301, a PTK7-targeted ADC. The company entered into an exclusive licensing agreement with Ipsen for tovorafenib commercialization outside the U.S.

For 2025, Day One aims to grow OJEMDA revenue, advance its clinical trials, pursue business development opportunities, and maintain a self-sustaining financial position. Full financial results for Q4 and the full year 2024 will be issued in February 2025.

Day One Biopharmaceuticals (Nasdaq: DAWN), a company focused on developing targeted therapies for life-threatening diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Jeremy Bender, the company's CEO, will deliver a presentation on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time.

Interested parties can access a live audio webcast of the presentation through the Events & Presentations section on Day One's website. The webcast recording will remain available for replay for 30 days after the live presentation.

Day One Biopharmaceuticals (Nasdaq: DAWN) announced that co-founder and Head of Research & Development, Dr. Samuel Blackman, will retire at the end of 2024. He will continue as a strategic advisor while the company searches for a new Head of R&D. Under Dr. Blackman's leadership since 2018, Day One acquired and developed tovorafenib, which received FDA approval in April 2024. The company, focused on developing targeted therapies for life-threatening diseases, will have Chief Medical Officer Dr. Elly Barry lead the clinical and medical teams during the transition period.